Vistagen's Social Anxiety Nasal Spray Trial Sends Stock Price Soaring
San Francisco-based pharmaceutical company Vistagen experienced a surge in its stock price of over 1,000% after announcing positive results from a Phase III trial for its nasal spray in treating social anxiety disorder. The trial demonstrated statistically significant differences in subjective distress scores and clinician-assessed responders between the experimental drug and placebo.